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There is currently no comprehensive meningococcal vaccine, due to difficulties in immunizing
against organisms expressing serogroup B capsules. To address this problem, subcapsular
antigens, particularly the outer-membrane proteins (OMPs), are being investigated as candidate
vaccine components. If immunogenic, however, such antigens are often antigenically variable,
and knowledge of the extent and structuring of this diversity is an essential part of vaccine
formulation. Factor H-binding protein (fHbp) is one such protein and is included in two vaccines
under development. A survey of the diversity of the fHbp gene and the encoded protein in a
representative sample of meningococcal isolates confirmed that variability in this protein is
structured into two or three major groups, each with a substantial number of alleles that have
some association with meningococcal clonal complexes and serogroups. A unified nomenclature
scheme was devised to catalogue this diversity. Analysis of recombination and selection on the
allele sequences demonstrated that parts of the gene are subject to positive selection, consistent
with immune selection on the protein generating antigenic variation, particularly in the C-terminal
region of the peptide sequence. The highest levels of selection were observed in regions
corresponding to epitopes recognized by previously described bactericidal monoclonal
antibodies.
INTRODUCTION
Meningococcal disease, caused by the Gram-negative
bacterium Neisseria meningitidis, is an important cause of
morbidity and mortality worldwide, with most disease
being due to meningococci expressing one of five capsular
polysaccharide antigens corresponding to serogroups A, B,
C, Y and W135. Although serogroup B meningococci are a
major cause of disease, particularly in industrialized
countries (Jones, 1995; Pollard et al., 2001; Trotter et al.,
2007), there is currently no vaccine against them due to the
poor immunogenicity of the serogroup B capsular
polysaccharide. This may be a consequence of its similarity
to host antigens, which also raises concerns as to the safety
of serogroup B polysaccharide as a vaccine component
(Finne et al., 1983). A variety of subcapsular cellular
components, particularly outer-membrane proteins
(OMPs), have been evaluated as possible alternative
vaccine antigens (Jodar et al., 2002). These have included
outer-membrane vesicle (OMV) vaccines that contain
PorA, which have been used to target single-clone
epidemics of meningococcal disease in Cuba, Norway
and New Zealand with some success (Bjune et al., 1991;
O’Hallahan et al., 2005; Rodriguez et al., 1999). A major
issue is the antigenic variability of OMPs, which compli-
cates the development of vaccines with broad coverage.
PorA, for example, has two major regions of antigenic
variability (Russell et al., 2004) with 188 and 517 different
peptide sequences in each region described by January 2009
(http://neisseria.org/nm/typing/).
Wider coverage against variable antigens can be attained by
inclusion of multiple variants in vaccine formulations, and
multivalent PorA vaccines such as NonaMen have been
developed (van den Dobbelsteen et al., 2007). For vaccine
formulations such as this, it is necessary to have detailed
molecular epidemiological information about the current
and most frequently occurring strains in the population.
Alternatively, more conserved antigens, such as Neisseria
adhesin A (NadA) and Neisseria surface protein A (NspA)
(Comanducci et al., 2002; Martin et al., 1997) and, despite
its variability (Rokbi et al., 2000), transferrin-binding
protein B (TbpB) (Ala’Aldeen & Borriello, 1996), have
been considered as candidates.
The vaccine candidate lipoprotein 2086 (LP2086) was
discovered by an iterative process of immunization
Abbreviations: fH, factor H; fHbp, factor H-binding protein; v, omega
(dN dS); ST, sequence type.
Two supplementary figures, showing distribution of clonal complexes
within fHbp peptide alleles and a neighbour-joining tree constructed
from aligned peptide sequences indicating association with clonal
complex, are available with the online version of this paper.
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purification (Bernfield et al., 2002; Fletcher et al., 2004).
It was also identified as genome-derived neisserial antigen
1870 (GNA1870) (Masignani et al., 2003) by the techni-
que known as ‘reverse vaccinology’ (Rappuoli, 2000).
Subsequently, it has been given the name factor H-binding
protein (fHbp) because of its role in modulating the
activity of the alternative complement pathway, where it
binds the regulatory protein factor H (fH) (Madico et al.,
2006). fH has a critical role in maintaining homeostasis of
the complement system and also, by attachment to host
cells and tissue, in preventing potential damage to them by
inhibiting complement activation (Rodrı ´guez de Co ´rdoba
et al., 2004). Several organisms, including N. meningitidis,
mimic human tissue by recruiting fH and coating their
surface, thereby avoiding complement-mediated lysis
(Lambris et al., 2008; Schneider et al., 2006). In the case
of the meningococcus, fHbp is the only receptor for fH on
its surface (Schneider et al., 2009). The protein is present in
all meningococci, although levels of expression may vary in
different isolates (Fletcher et al., 2004; Masignani et al.,
2003). In comparison with other vaccine antigens, it is
relatively sparse in its epitope surface-exposure in most
meningococcal strains (Welsch et al., 2004). Expression of
fHbp has been found to be key for survival in ex vivo
human blood and human serum, particularly in high-
expressing strains (Seib et al., 2009; Welsch et al., 2008).
Structurally, fHbp is a surface-exposed 29 kDa globular
lipoprotein composed of two b-barrels connected by a
short linker and is bound to the outer membrane by an N-
terminal lipid anchor (Cantini et al., 2009; Mascioni et al.,
2009; Schneider et al., 2009). Recent analysis of the fH–
fHbp interaction indicates that the fH recognition site
spans the whole surface of fHbp and that previously
described bactericidal epitope sites do not lie in this region,
but epitopes that bind to antibodies that affect fH binding
are found around the edge of the site (Schneider et al.,
2009).
The protein is a principal component of two recombinant
protein vaccines in clinical trials at the time of writing. It is
unique as a vaccine candidate in that it is able to elicit
serum antibodies that activate classical complement
pathway bacteriolysis and also prevent fH binding to the
meningococcal cell surface, thus making it more suscept-
ible to bactericidal activity (Madico et al., 2006; Welsch
et al., 2008). Like the related human-restricted organism
Neisseria gonorrhoeae, there is specificity of binding to
human fH (Granoff et al., 2009; Ngampasutadol et al.,
2008). This may help to explain the higher bactericidal
titres obtained when using vaccine-induced antibodies with
rabbit complement versus human complement and also the
organisms’ exclusively human-related pathogenicity.
In the present study, variation of fHbp in a reference set of
diverse meningococcal isolates was surveyed. The asso-
ciation of particular variants with clonal complex and
serogroup was established, and the levels of recombination
and selection acting on it were determined. Also, a novel,
unified nomenclature scheme was developed that was
independent of subfamily/variant and a Web-accessible
database established to facilitate querying of sequences and
submission of new allele sequences.
METHODS
Isolates. The 107 meningococci surveyed were representative of
bacteria isolated worldwide in the latter half of the twentieth century,
obtained from both patients with meningococcal disease and carriers
(Maiden et al., 1998). Two previously published N. gonorrhoeae
protein sequences: YP_002793564 and EEH61327, from GenBank
were also used as part of the analysis.
Amplification of the fHbp gene and nucleotide sequence
determination. Amplification of an approximately 900 bp region
including the fHbp gene and immediately flanking regions was carried
out using the Long 5UNI 2086 and 3UNI pair of primers (Fletcher
et al., 2004). The PCRs were performed in 50 ml amplification
reaction volumes using Taq polymerase (Qiagen) with 33 cycles of
95 uC for 50 s, 59 uC for 50 s, and 72 uC for 50 s with a final
extension step of 72 uC for 7 min. The amplicons were purified by
20% PEG/2.5 M NaCl precipitation and then used as templates for
10 ml dideoxynucleotide sequencing reactions using BigDye Ready
Reaction Mix (Applied Biosystems). Oligonucleotide primers specific
for each of the subfamilies A and B were used to amplify internal
fragments of the purified amplified gene products: (for subfamily A)
592086forseq (59-TAT GAC TAG GAG CAA ACC TG-39), 392086for-
seq (59-TAC TGT TTG CCG GCG ATG-39), 2086interforseq59LA
primer (59-AGC TCA TTA CCT TGG AGA GCG GA-39); (for
subfamily B) 2086seq39BLA primer (59-TTC GGA CGG CAT TTT
CAC AAT GG-39) and 2086seqBinternal (59-GGC GAT TTC AAA
TGT TCG ATT T-39). Cycling conditions were 30 cycles of 96 uC for
10 s, 50 uC for 5 s and 60 uC for 4 min. Separation of the labelled
extension products was carried out on a 3730 capillary DNA analyser
(Applied Biosystems) at the Department of Zoology Sequencing
Facility, University of Oxford.
Analysis of sequence data. Assembly and editing of nucleotide
sequence data were carried out using the Staden suite of software
(Staden, 1996). Reformatted nucleotide sequences were visualized,
aligned and translated manually using SeqLab, part of the GCG
Wisconsin Package (Womble, 2000) [Version 10.3 for Unix
(Accelrys)]. The alignment was based on amino acid sequence
similarity with codon integrity maintained. A web-based front end to
the NRDB program (written by Warren Gish, Washington
University) was used to compare nucleotide and amino acid
sequences to find those that were identical (http://pubmlst.org/
analysis/).
The MEGA 3.1 program (Kumar et al., 2004) was used to calculate the
overall mean distances as well as the within- and between-group
distances for sequences using the Kimura two-parameter model for
nucleotide sequences and p-distances for amino acid sequences, and
also to produce distance matrix-based neighbour-joining trees. The
reliability of the inferred trees was assessed by the bootstrap test with
2000 replications. MEGA 3.1 implements Felsenstein’s bootstrap test
evaluated using Efron’s bootstrap resampling method. In the
bootstrap test of phylogeny, a matrix of m sequences6n (nucleo-
tides/peptides) is sampled with replacement (bootstrapping). These
new sequences are reconstructed into a tree using the previously used
phylogenetic method and the topology is compared with the original
tree. This procedure is repeated 2000 times, and the percentage of
times a particular interior branch is the same between the original tree
and the bootstrap tree is given. Boostrapping is a means of assessing
C. Brehony, D. J. Wilson and M. C. J. Maiden
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probability of interior branches being ‘correct’ (generally 95% or
higher).
The software package CLONALFRAME version 1.1, which implements a
statistical model for inferring bacterial microevolution, was used for
phylogenetic analysis and to identify regions likely to have undergone
homologous recombination (Didelot & Falush, 2007). CLONALFRAME
performs inference in a Bayesian framework which assumes a
standard neutral coalescent model whereby the bacteria in the sample
come from a constant-sized population in which each bacterium is
equally likely to reproduce, irrespective of its previous history. The
key assumption is that recombination events introduce a constant
rate of substitutions to a contiguous region of sequence. Six
independent runs, each with 250000 iterations, 100000 burn-in
iterations and with every hundredth tree sampled, were used to derive
a 75% majority-rule consensus tree. PAUP* version 4.0b10 for Unix
(Swofford, 1998) was used to construct phylogenetic trees using the
maximum-likelihood method. CLONALFRAME and maximum-like-
lihood tree outputs were imported and further annotated in MEGA 3.1.
Associations between subfamily/allele and clonal complex/serogroup
were analysed using Fisher’s exact test with Bonferroni correction
applied as appropriate, with calculations performed with the R
program version 2.7.1 (http://www.r-project.org/). Simpson’s index
of diversity (D) was used to assess the level of diversity of each
subfamily/variant. It gives the probability that any two randomly
selected individuals drawn from an infinitely large community belong
to different species, or in the case of this study, the probability that
isolates drawn from a population belong to different allele types
(Hunter & Gaston, 1988; Simpson, 1949). The bias-corrected form of
the formula used is as follows:
D~1{
P
n(n{1)
N(N{1)
Where N is total number of isolates and n is total number of isolates
of a particular genetic type. The value of the index ranges from zero to
one, such that the nearer to one the greater the diversity and the
nearer to zero the less the diversity. The 95% confidence intervals
(CIs) for these indices were calculated as described by Grundmann
et al. (2001). Non-overlapping CIs indicate a significant difference
in D.
Analysis of selection pressures. The START2 program (Jolley et al.,
2001) (http://pubmlst.org/software/analysis/start2/) was used for tests
of recombination by the maximum chi-squared test and for selection
using the ratio of non-synonymous to synonymous nucleotide
substitutions (dN:dS ratio). The OMEGAMAP program, which employs
a Bayesian method to estimate the selection parameter v (dN:dS) and
the recombination rate r from gene sequences by use of reversible
jump Monte Carlo Markov Chain (Wilson & McVean, 2006), was
used to detect selection and recombination by inferring the posterior
distributions of v and r along the gene. The means of the posterior
distributions were used as a point estimates for v and r. The per-site
posterior probability of positive selection was also used to summarize
the posterior distribution of v. Three independent OMEGAMAP runs,
each with 1000000 iterations and a thinning interval of 100, were
compared to assess convergence and combined. Output from the
OMEGAMAP runs was used to visualize possible selection acting on the
sequence by means of fireplots and graphs indicating the posterior
probability of positive selection along the sequence. Fireplots visualize
the posterior probability on log(v)o rv along the sequence using a
colour gradient, where a higher posterior density is represented by
more intense colour (closer to white) and lower posterior density is
represented by less intense colour (closer to red). These plots were
produced using the R program version 2.7.1 (http://www.r-project.
org/). The point estimate of v was used to colour a 3D pdb file of the
solution structure of a complex between a subfamily B/variant 1
GNA1870/fHbp protein and a region of the fH protein (Schneider
et al., 2009) (http://www.rcsb.org/pdb/home/home.do Protein Data
Bank code 2W81).
fHbp database. Unique nucleotide and peptide sequences were
arbitrarily assigned allele numbers in order of discovery. A database
was established containing these allele sequences obtained as part of
this study, from direct submissions from collaborators or by
interrogation of the GenBank database. AGDBNET antigen sequence
software for web-based bacterial typing was used to do this (http://
pubmlst.org/software/database/agdbnet/). It allows simultaneous
BLAST querying of multiple loci using either nucleotide or peptide
sequences (Jolley & Maiden, 2006).
RESULTS
Diversity of fHbp gene and protein
The fHbp gene was found in all 107 isolates, and among
these, a total of 28 unique gene sequences encoding 27
different amino acid sequences were identified (Table 1).
Unique peptide and nucleotide sequences were arbitrarily
assigned allele numbers in order of discovery and entered
into a database (http://neisseria.org/nm/typing/fhbp/),
providing a comprehensive repository of reported fHbp
diversity.
On the basis of 798 unambiguously aligned nucleotides
there were a total of 299 variable nucleotide sites within
these sequences (Fig. 1). Two broad groups of sequence
variant types were evident from this alignment. This
corresponds to the previously identified groups: subfamily
A/variant 2 and subfamily B/variant 1 (Fletcher et al.,
2004). Within subfamily A/variant 2 there were five
putative subfamily A/variant 3 sequences which differed
from the rest of subfamily A/variant 2 mainly in the N-
terminal first 100 amino acids (Masignani et al., 2003). The
subfamily A/variant 2 (including variant 3) was signific-
antly more diverse in terms of allele types than subfamily
B/variant 1 [D50.91 (95% CIs 0.87–0.95) versus 0.80
(95% CIs 0.75–0.85), respectively].
There was 63% nucleotide sequence identity shared
between the two main groups and larger identity within
them: 85% nucleotide site identity within subfamily
A/variant 2 and 87% nucleotide site identity within
subfamily B/variant 1. The overall mean Kimura two-
parameter p-distance among all gene sequences was 0.165.
The within-group mean p-distances were 0.046 for
subfamily A/variant 2 and 0.032 for subfamily B/variant
1, with a mean p-distance between the two subfamilies/
variants of 0.302. There was 56% deduced amino acid
sequence identity shared between the two groups. Within
subfamily A/variant 2 there was 81% amino acid site
identity and within subfamily B/variant 1 there was 87%
amino acid site identity. The overall mean p-distance
among the amino acid sequences was 0.17. The within-
group mean p-distances for subfamily A/variant 2 and
Meningococcal factor H-binding protein diversity
http://mic.sgmjournals.org 4157Table 1. Study isolates and association with clonal complex, sequence type (ST), year, country, disease, serogroup, peptide allele,
nucleotide allele and subfamily/variant
Isolate
name
Complex ST Subfamily/
variant
Year Country Disease Serogroup Peptide
allele
Nucleotide
allele
393 ST-1 complex 1 SubB/v1 1968 Greece Carrier A 4 4
20 ST-1 complex 1 SubB/v1 1963 Niger Invasive (unspecified/other) A 4 4
129E ST-1 complex 1 SubB/v1 1964 West Germany Invasive (unspecified/other) A 4 4
254 ST-1 complex 1 SubB/v1 1966 Djibouti Invasive (unspecified/other) A 4 4
106 ST-1 complex 1 SubB/v1 1967 Morocco Invasive (unspecified/other) A 4 4
6748 ST-1 complex 1 SubB/v1 1971 Canada Invasive (unspecified/other) A 4 4
S5611 ST-1 complex 1 SubB/v1 1977 Australia Invasive (unspecified/other) A 4 4
79126 ST-1 complex 3 SubB/v1 1979 China Invasive (unspecified/other) A 38 37
79128 ST-1 complex 3 SubB/v1 1979 China Invasive (unspecified/other) A 38 37
371 ST-1 complex 1 SubB/v1 1980 India Invasive (unspecified/other) A 4 4
322/85 ST-1 complex 2 SubB/v1 1985 East Germany Invasive (unspecified/other) A 14 14
120M ST-1 complex 1 SubB/v1 1967 Pakistan Meningitis and septicaemia A 4 4
139M ST-1 complex 1 SubB/v1 1968 Philippines Unspecified A 1 1
BZ 133 ST-1 complex 1 SubB/v1 1977 Netherlands Invasive (unspecified/other) B 4 4
890326 ST-103 complex 28 SubA/v2 1989 Netherlands Invasive (unspecified/other) Z 25 25
NG P20 ST-11 complex 11 SubB/v1 1969 Norway Invasive (unspecified/other) B 5 5
D1 ST-11 complex 11 SubA/v2 1989 Mali Carrier C 22 22
M597 ST-11 complex 11 SubA/v2 1988 Israel Invasive (unspecified/other) C 22 22
BRAZ10 ST-11 complex 11 SubA/v2 1976 Brazil Unspecified C 22 22
F1576 ST-11 complex 11 SubA/v2 1984 Ghana Unspecified C 22 22
500 ST-11 complex 11 SubA/v2 1984 Italy Unspecified C 22 22
MA-5756 ST-11 complex 11 SubA/v3 1985 Spain Unspecified C 67 54
90/18311 ST-11 complex 11 SubA/v2 1990 Scotland Unspecified C 22 22
L93/4286 ST-11 complex 11 SubA/v2 1993 England Invasive (unspecified/other) C 95 92
38VI ST-11 complex 11 SubA/v3 1964 USA Unspecified B 98 95
860800 ST-167 complex 29 SubA/v2 1986 Netherlands Invasive (unspecified/other) Y 23 23
EG 328 ST-18 complex 18 SubB/v1 1985 East Germany Invasive (unspecified/other) B 37 36
EG 327 ST-18 complex 19 SubA/v2 1985 East Germany Invasive (unspecified/other) B 33 41
1000 ST-18 complex 20 SubB/v1 1988 USSR Invasive (unspecified/other) B 5 5
528 ST-18 complex 18 SubB/v1 1989 USSR Invasive (unspecified/other) B 37 36
E26 ST-198 complex 39 SubA/v3 1988 Norway Carrier X 94 91
A22 ST-22 complex 22 SubA/v2 1986 Norway Carrier W-135 16 16
71/94 ST-23 complex 23 SubA/v2 1994 Norway Invasive (unspecified/other) Y 25 25
297-0 ST-254 complex 49 SubB/v1 1987 Chile Carrier B 13 13
NG F26 ST-269 complex 14 SubA/v2 1988 Norway Carrier B 19 19
NG 6/88 ST-269 complex 13 SubA/v2 1988 Norway Invasive (unspecified/other) B 32 40
44/76 ST-32 complex 32 SubB/v1 1976 Norway Invasive (unspecified/other) B 1 1
NG 080 ST-32 complex 32 SubB/v1 1981 Norway Invasive (unspecified/other) B 1 1
NG144/82 ST-32 complex 32 SubB/v1 1982 Norway Invasive (unspecified/other) B 1 1
BZ 83 ST-32 complex 34 SubB/v1 1984 Netherlands Invasive (unspecified/other) B 1 1
EG 329 ST-32 complex 32 SubB/v1 1985 East Germany Invasive (unspecified/other) B 1 1
BZ 169 ST-32 complex 32 SubB/v1 1985 Netherlands Invasive (unspecified/other) B 1 1
NG PB24 ST-32 complex 32 SubB/v1 1985 Norway Invasive (unspecified/other) B 1 1
8680 ST-32 complex 32 SubB/v1 1987 Chile Invasive (unspecified/other) B 13 13
204/92 ST-32 complex 33 SubB/v1 1992 Cuba Invasive (unspecified/other) B 1 1
196/87 ST-32 complex 32 SubB/v1 1987 Norway Unspecified C 1 1
E32 ST-334 complex 31 SubA/v2 1988 Norway Carrier Z 19 19
SWZ107 ST-35 complex 35 SubA/v2 1986 Switzerland Invasive (unspecified/other) B 16 16
NG E31 ST-364 complex 15 SubA/v2 1988 Norway Carrier B 34 43
DK 353 ST-37 complex 37 SubA/v2 1962 Denmark Invasive (unspecified/other) B 24 24
BZ 232 ST-37 complex 38 SubA/v2 1964 Netherlands Invasive (unspecified/other) B 24 24
A4/M1027 ST-4 complex 4 SubB/v1 1937 USA Invasive (unspecified/other) A 5 5
10 ST-4 complex 4 SubB/v1 1963 Burkina Faso Invasive (unspecified/other) A 5 5
26 ST-4 complex 4 SubB/v1 1963 Niger Invasive (unspecified/other) A 5 5
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name
Complex ST Subfamily/
variant
Year Country Disease Serogroup Peptide
allele
Nucleotide
allele
255 ST-4 complex 4 SubB/v1 1966 Burkina Faso Invasive (unspecified/other) A 5 5
S3131 ST-4 complex 4 SubB/v1 1973 Ghana Invasive (unspecified/other) A 5 5
690 ST-4 complex 4 SubB/v1 1980 India Invasive (unspecified/other) A 5 5
C751 ST-4 complex 4 SubB/v1 1983 Gambia Invasive (unspecified/other) A 5 5
1014 ST-4 complex 4 SubB/v1 1985 Sudan Invasive (unspecified/other) A 5 5
2059001 ST-4 complex 4 SubB/v1 1990 Mali Invasive (unspecified/other) A 5 5
D8 ST-4 complex 4 SubB/v1 1990 Mali Invasive (unspecified/other) A 5 5
243 ST-4 complex 4 SubB/v1 1966 Cameroon Unspecified A 5 5
NG H36 ST-41/44 complex 47 SubA/v2 1988 Norway Carrier B 19 19
NG E30 ST-41/44 complex 44 SubA/v2 1988 Norway Carrier B 32 42
BZ 147 ST-41/44 complex 48 SubB/v1 1963 Netherlands Invasive (unspecified/other) B 4 4
BZ198 ST-41/44 complex 41 SubB/v1 1986 Netherlands Invasive (unspecified/other) B 5 5
88/03415 ST-41/44 complex 46 SubB/v1 1988 Scotland Invasive (unspecified/other) B 14 14
91/40 ST-41/44 complex 42 SubB/v1 1991 New Zealand Invasive (unspecified/other) B 14 14
400 ST-41/44 complex 40 SubB/v1 1991 Austria Invasive (unspecified/other) B 14 14
AK50 ST-41/44 complex 41 SubB/v1 1992 Greece Invasive (unspecified/other) B 4 4
M-101/93 ST-41/44 complex 41 SubB/v1 1993 Iceland Invasive (unspecified/other) B 4 4
931905 ST-41/44 complex 41 SubB/v1 1993 Netherlands Invasive (unspecified/other) B 14 14
50/94 ST-41/44 complex 45 SubB/v1 1994 Norway Invasive (unspecified/other) B 4 4
M40/94 ST-41/44 complex 41 SubB/v1 1994 Chile Invasive (unspecified/other) B 35 32
N45/96 ST-41/44 complex 41 SubB/v1 1996 Norway Invasive (unspecified/other) B 1 1
NG H15 ST-41/44 complex 43 SubA/v2 1988 Norway Carrier B 19 19
80049 ST-5 complex 5 SubB/v1 1963 China Carrier A 39 38
F4698 ST-5 complex 5 SubB/v1 1987 Saudi Arabia Carrier A 14 14
153 ST-5 complex 5 SubA/v2 1966 China Invasive (unspecified/other) A 22 22
154 ST-5 complex 6 SubB/v1 1966 China Invasive (unspecified/other) A 36 35
S4355 ST-5 complex 5 SubB/v1 1974 Denmark Invasive (unspecified/other) A 5 5
7891 ST-5 complex 5 SubB/v1 1975 Finland Invasive (unspecified/other) A 5 5
11-004 ST-5 complex 5 SubB/v1 1984 China Invasive (unspecified/other) A 5 5
H1964 ST-5 complex 5 SubB/v1 1987 UK Invasive (unspecified/other) A 5 5
92001 ST-5 complex 7 SubB/v1 1992 China Invasive (unspecified/other) A 5 5
14/1455 ST-5 complex 5 SubB/v1 1970 USSR Unspecified A 14 14
IAL2229 ST-5 complex 5 SubB/v1 1976 Brazil Unspecified A 5 5
F6124 ST-5 complex 5 SubA/v2 1988 Chad Invasive (unspecified/other) A 25 25
860060 ST-750 complex 24 SubA/v3 1986 Netherlands Invasive (unspecified/other) X 84 69
BZ 10 ST-8 complex 8 SubA/v2 1967 Netherlands Invasive (unspecified/other) B 18 39
B6116/77 ST-8 complex 10 SubA/v2 1977 Iceland Invasive (unspecified/other) B 16 16
BZ 163 ST-8 complex 9 SubA/v2 1979 Netherlands Invasive (unspecified/other) B 16 16
G2136 ST-8 complex 8 SubA/v2 1986 England Invasive (unspecified/other) B 16 16
AK22 ST-8 complex 8 SubA/v2 1992 Greece Invasive (unspecified/other) B 16 16
SB25 ST-8 complex 8 SubA/v2 1990 South Africa Invasive (unspecified/other) C 16 16
94/155 ST-8 complex 66 SubA/v2 1994 New Zealand Invasive (unspecified/other) C 16 16
312 901 ST-8 complex 8 SubA/v2 1996 England Invasive (unspecified/other) C 16 16
CN100 Unassigned 21 SubB/v1 1941 England Invasive (unspecified/other) A 4 4
NG E28 Unassigned 26 SubB/v1 1988 Norway Carrier B 14 14
3906 Unassigned 17 SubA/v2 1977 China Invasive (unspecified/other) B 18 39
NG 4/88 Unassigned 30 SubB/v1 1988 Norway Invasive (unspecified/other) B 4 4
NG 3/88 Unassigned 12 SubA/v3 1988 Norway Invasive (unspecified/other) B 96 93
NG G40 Unassigned 25 SubA/v2 1988 Norway Carrier B 24 24
EG 011 Unassigned 36 SubA/v2 1986 East Germany Invasive (unspecified/other) B 24 24
NG H41 Unassigned 27 SubA/v2 1988 Norway Carrier B 25 25
DK 24 Unassigned 16 SubA/v2 1940 Denmark Invasive (unspecified/other) B 97 94
NG H38 Unassigned 36 SubA/v2 1988 Norway Carrier B 24 24
Table 1. cont.
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http://mic.sgmjournals.org 4159Fig. 1. Aligned fHbp peptide allele variable sites. Alleles fHbp1, 4, 5, 13, 14 and 35–39 are subfamily B/variant 1; alleles fHbp16, 18, 19, 22–25, 32–
34, 95 and 97 are subfamily A/variant 2; and alleles fHbp67, 84, 94, 96 and 98 are subfamily A/variant 3. The sequences in italic type indicate the N-
terminal first 100 aa.
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5subfamily B/variant 1 were 0.052 and 0.038, respectively.
The mean p-distance between the two subfamilies/variants
was 0.31. Without the subfamily A/variant 3 sequences,
subfamily A/variant 2 nucleotide sequence identity was
90% and amino acid site identity was 88%.
Sequence variability was found throughout the gene and
encoded protein (Fig. 1). There was a marked difference in
variability, however, between the N-terminal first ~105 aa
and the C-terminal region of ~161 aa, where sequences
were more variable. The amino acid sequence identity of
the C-terminal region between the two groups was 48%;
however, there was more identity within the groups
(subfamily A/variant 2, 87%; subfamily B/variant 1,
84%). For the N-terminal region there was 67% amino
acid identity between the two subfamilies/variants, and
70% within subfamily A/variant 2 and 93% within
subfamily B/variant 1. In the absence of the subfamily A/
variant 3 sequences, for subfamily A/variant 2, there was
90% amino acid identity in the C-terminal region and
86% in the N-terminal region.
The amino acid Glu/Lys at position 154 was present in
subfamily B/variant 1 isolates but not subfamily A/variant 2
isolates (Fig. 1). There was an absence, in subfamily A/
variant 2 isolates, of Arg
204 (here at amino acid 212),
considered to be key in antibody binding in the subfamily
B/variant 1 antigen (Giuliani et al., 2005), where it is
substituted with serine. There were 81% of subfamily B/
variant 1 isolates that contained Arg
204; the rest had a
histidine residue at this position. Two subfamily B/variant
1 isolates (IDs EG328 and 528; peptide 37) had a
substitution of a G for a T in the final stop codon and
were thus extended for a further nine bases. The N-
terminal region separates the subfamily A/variant 3 isolate
sequences from the other subfamilies/variants (Fig. 1).
Subfamily A/variant 3 sequences contained an insertion at
amino acids 67–69 of lysine, aspartic acid and asparagine,
not present in the other variants. This insertion has
previously been noted as being present in a subset of
subfamily A protein sequences (Fletcher et al., 2004). Three
of the five subfamily A/variant 3 sequences also contained a
5 aa glycine-rich insertion at the N-terminal end. This
insertion has been found in sequences of both subfamilies/
variants (Fletcher et al., 2004), and is thought to be used as
a means of lengthening the chain that attaches the folded
protein to accommodate differences in lipooligosaccharide
length on the outer membrane (Mascioni et al., 2009).
Genealogical analysis using CLONALFRAME, and phylogenies
constructed with neighbour-joining (Supplementary Fig.
S2) and maximum-likelihood methods (not shown),
resolved protein and nucleotide sequences into two major
groups, with the variant 3 isolates branching off from the
rest of subfamily A/variant 2 (Fig. 2). CLONALFRAME gives
equal weight to genetic events that result in one nucleotide
change, and single horizontal genetic exchange events that
result in many nucleotide changes, and did not separate the
putative subfamily A/variant 3 isolate sequences from the
other subfamily A/variant 2 isolates (Fig. 2), although they
were more distant from them in neighbour-joining
(Supplementary Fig. S2) and maximum-likelihood phylo-
genies (data not shown).
Fig. 2. A 75% majority-rule consensus CLONALFRAME radial tree of
107 aligned nucleotide sequences with colour coding according
to clonal complex and confidence values for nodes. A node is
defined as the most recent common ancestor of the isolates in the
branch above it.
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The distribution of subfamily/variant alleles was not
random among clonal complexes, showing some clustering
with particular meningococcal genotypes (Fig. 2 and
Supplementary Fig. S1). For example, the sequence type
(ST)-11 complex was associated with subfamily A/variant 2
and in particular a cluster within this subfamily/variant (six
of eight isolates were fHbp peptide 22; Fisher’s exact test
both P,0.005). Similarly, the ST-8 complex was found to
be associated only with this subfamily/variant and seven of
eight isolates had the fHbp 16 peptide (Fisher’s exact test
P,0.005). The serogroup A-associated complexes ST-4
and ST-5 were clustered together and associated mainly
with subfamily B/variant 1. The ST-4 complex was
particularly homogeneous as all isolates had the fHbp 5
peptide (Fisher’s exact test P,0.005). All the ST-32
complex isolates were found associated with subfamily B/
variant 1, with nine of 10 isolates having the fHbp 1
peptide type (Fisher’s exact test P,0.005). The ST-1
complex was significantly associated with fHbp peptide 4
(10 of 14 isolates, Fisher’s exact test P, 0.005). The other
main hyperinvasive lineage, the ST-41/44 complex, was
more diverse with respect to the subfamilies/variants
observed.
Similarly, there was a relationship between serogroup
(particularly non-B serogroups) and variants/subfamilies
(Table 1), although this was at least in part due to the
known association of clonal complex with serogroup
(Trotter et al., 2007). A total of 55% of subfamily B/
variant 1 were serogroup A (Fisher’s exact test P,0.005)
compared with 4% for subfamily A/variant 2. Serogroup C
was found in 1.6% of subfamily B/variant 1, while it
accounted for 35% of subfamily A/variant 2 (Fisher’s exact
test P,0.005). There were no W-135, Y or Z subfamily B/
variant 1 types, while each serogroup accounted for 4% of
subfamily A/variant 2 isolates. Serogroup B was more
evenly distributed, accounting for 50% of subfamily A/
variant 2 isolates and 44% of subfamily B/variant 1
isolates. However, 70% of serogroup B disease-associated
isolates were subfamily B/variant 1.
Fig. 3. Representation of fHbp gene recombination events (a–d). The nucleotide sequence of the fHbp gene is on the x axis,
with the red line indicating the probability for an import from 0 to 1 (y axis). The panels depict genetic events above nodes A, B,
C and D shown in the 75% majority-rule consensus CLONALFRAME tree panel (Fig. 2). Each inferred substitution is indicated by a
cross, the intensity of which indicates the posterior probability for that substitution. In (a), horizontal genetic exchange is
depicted occurring from base 300 to base 500 and from base 550 to base 800; in (b), from base 450 to base 600; in (c),
horizontal genetic exchange is depicted occurring from base 100 to base 250 and in (d) at about 200 and 300 bases.
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Maximum chi squared analysis identified putative recomb-
ination sites after nucleotide sites 281 and 326.
CLONALFRAME analysis indicated strong evidence of hori-
zontal genetic exchange in the C-terminal region from
around 300 bp onwards (node A in Figs 2 and 3a). Also, in
the N-terminal region of subfamily A/variant 3 sequences
there was strong evidence of lateral gene transfer which
presumably gave rise to this variant within the subfamily A/
variant 2 group (nodes C and D, Fig. 3c, d). Other points
of recombination were identified, including above node B,
which contains subfamily A/variant 2 sequences (Fig. 3b).
The fHbp locus had an average dN:dS ratio of 0.35,
indicating a level of purifying selection against amino acid
change. Previous estimates have been 0.51±0.7 (Bambini
et al., 2009) and comparable to that of other antigenic
genes such as fetA (0.314) (Thompson, 2001). Codon-by-
codon analysis of selection on the gene was possible using
OMEGAMAP. Separate analyses for each of the subfamilies/
variants, including variant 3, indicated that in the C-
terminal region (after ~ 318 nt encoding 106 aa) there was
diversifying immune selection (v .1) acting on particular
areas in each of the subfamilies/variants (Fig. 4a–f).
Subfamily B/variant 1 and subfamily A/variant 2 (not
including variant 3) shared one positively selected codon
(147 and 151 in subfamily B/variant 1 and subfamily A/
variant 2, respectively). Subfamily B/variant 1 displayed
positive selection at the four codons 146–149 (v 3.41–3.52)
and also at codons 195–204 (v 1.02–1.66). Subfamily A/
variants 2 and 3 shared the positively selected sites from
codons 169–181. The per-site point estimate of v inferred
for each of the subfamily/variant isolates was used to
colour a 3D pdb file of the solution structure of a complex
between a subfamily B/variant 1 GNA1870/fHbp protein
and a region of the fH protein (code 2W81) (Schneider et
al., 2009). The temperature colouring of the protein
enabled the demonstration of the regions under positive
selection on the 3D model (Fig. 5a, b and c). These regions
did not overlap with residues involved in interactions with
the fH molecule (Schneider et al., 2009).
DISCUSSION
An ideal vaccine candidate provides cross-protection
against all variants of a targeted pathogen. To date,
proteins suggested as components of meningococcal
vaccines either do not elicit protective immune responses
or, like fHbp, are variable (Jodar et al., 2002).
Consequently, it is important to catalogue this diversity
before a vaccine formulation is finalized to ensure
maximum vaccine coverage. For fHbp a number of studies
have been performed to achieve this (Bambini et al., 2009;
Murphy et al., 2009); however, a universal agreed
nomenclature is essential to enable comparisons among
different studies. Two different fHbp classification schemes
have been proposed: one classifies the protein variants of
fHbp (referred to as GNA1870) into three variant families,
named variants 1, 2 and 3 (Masignani et al., 2003), while
the other groups variants of the same protein (referred to
as LP2086) into subfamilies A and B (Fletcher et al., 2004).
Here, a unified nomenclature is proposed in which unique
fHbp peptide and nucleotide sequences are assigned
numbers arbitrarily and entered into a database that can
be queried and into which new sequences can be deposited
(http://neisseria.org/nm/typing/fhbp). Using this nomen-
clature as a basis, higher-order classifications can be
applied without confusion.
Understanding diversity also requires appropriate isolate
collections, with a sample frame appropriate to the
question addressed. For this reason, the present study
investigated the 107 meningococci used to establish
multilocus sequence typing (MLST), which includes the
globally important disease-associated hyperinvasive menin-
gococcal lineages of all serogroups from the latter half of
the twentieth century, which have been extensively
characterized (Callaghan et al., 2006; Maiden et al., 1998;
Thompson et al., 2003; Urwin et al., 2004). The number of
fHbp alleles in this set, 28 encoding 27 peptides, was
broadly similar to the number for other surface proteins
investigated: PorA (33 alleles encoding 33 peptides); PorB
(31 alleles encoding 28 peptides); FetA (33 alleles encoding
31 peptides); and Opa (90 alleles encoding 83 peptides)
(Callaghan et al., 2006; Urwin et al., 2004). The diversity of
fHbp resolved into two major clusters by the phylogenetic
approaches used (Fig. 2), as described previously (Fletcher
et al., 2004; Murphy et al., 2009), with evidence of a third
group (variant 3) (Masignani et al., 2003). While other
variants may be discovered by further studies, especially of
carried rather than disease-associated meningococci, com-
parison with published sequences from various sources
(GenBank, http://neisseria.org/nm/typing/fhbp) demon-
strated that the 107 isolates included all the major variant
clusters of the protein described to date. Of the previously
described groups, subfamily B/variant 1 was the most
prevalent (60%) among the 107 isolates. In other studies it
accounted for 54–70% of isolates (Beernink et al., 2007;
Fletcher et al., 2004; Jacobsson et al., 2006; Masignani et al.,
2003; Murphy et al., 2009; Welsch et al., 2004).
There was evidence that fHbp alleles and consequently
variant peptides are generated by horizontal genetic
exchange, as is the case for other meningococcal antigens
(Bennett et al., 2009; Derrick et al., 1999; Harrison et al.,
2008). Furthermore, the gene is also present in N.
gonorrhoeae, with the gonococcal fHbp sequences described
to date belonging to subfamily A/variant 2 group (Fletcher
et al., 2004; Masignani et al., 2003). It is possible that
subfamily A/variant 3 arose through a recombination event
with a DNA fragment donated from another member of
the genus Neisseria, an idea supported by a neighbour-
joining phylogenetic analysis of peptide sequences that
clustered the subfamily A/variant 3 sequences between two
gonococcal fHbp sequences and other subfamily A/variant
2 sequences (data not shown). Common gene pools have
Meningococcal factor H-binding protein diversity
http://mic.sgmjournals.org 4163Fig. 4. OMEGAMAP program output using subfamily A/variant 2 and subfamily B/variant 1 nucleotide sequences. (a), (b) and (c) depict fireplots of the
sitewise posterior distribution of log(v) for subfamily B, subfamily A (without variant 3) and subfamily A/variant 3 sequences, respectively. A fireplot
visualizes the posterior log(v) along the sequence using a colour gradient, where a higher posterior density is represented by more intense colour (closer
to white) and lower posterior density is represented by less intense colour (closer to red). (d), (e) and (f) depict the posterior probability of positive
selection (y axis, values 0 to 1) along the codon sequence (x axis) for subfamily B, subfamily A (without variant 3) and subfamily A/variant 3 sequences,
respectively. Note: variants 2 and 3 differ from subfamily B/variant 1 in length by +4 and +7 bp, respectively, e.g. residue 147 of variant 1 is at position
151 of subfamily A/variant 2 (e), and at position 154 of subfamily A/variant 3 (d).
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5been documented for other Neisseria antigens such as
PorB2, FetA and TbpB (Bennett et al., 2009; Derrick et al.,
1999; Harrison et al., 2008). In the case of PorB and TbpB,
different variant classes are thought to have arisen due to
inter-species recombination.
While N. gonorrhoeae appears to have an fHbp gene, it is
known to bind fH via porin proteins (Ngampasutadol et
al., 2008). Both meningococci and gonococci have
specificity for human fH, which may partly explain their
pathogenic restriction in humans (Granoff et al., 2009;
Welsch & Ram, 2008). The gene encoding fHbp has also
been detected in the commensal species Neisseria cinerea
and Neisseria lactamica, and a potential fHbp peptide has
been detected by Western blot analysis (Fletcher et al.,
2004; Masignani et al., 2003); however, the distribution of
the fHbp gene among the Neisseria and its function in the
non-pathogenic organisms are yet to be fully elucidated.
Despite the genetic and antigenic diversity of carried
populations of meningococci (Caugant & Maiden, 2009;
Yazdankhah & Caugant, 2004), most invasive meningo-
coccal disease is caused by a small number of clonal
complexes, known as the hyperinvasive lineages (Brehony
et al., 2007; Caugant, 2001; Yazdankhah et al., 2004). In
common with other variable antigens (Callaghan et al.,
2008; Harrison et al., 2008; Trotter et al., 2007; Urwin et al.,
2004), the distribution of fHbp variants was not random
among clonal complexes, with certain variants more likely
to be found in given hyperinvasive lineages, as seen in other
isolate collections (Bambini et al., 2009; Jacobsson et al.,
2006; Masignani et al., 2003). The ST-32 complex and
serogroup A were significantly associated with particular
subfamily B/variant 1 peptide alleles (1 and 5 respectively).
The ST-11 complex, which can be distinguished from other
hyperinvasive lineages by harbouring only tbpB isotype I
and lacking the opcA gene (Claus et al., 2001), was
significantly associated with subfamily A and peptide allele
type 22. Similarly, stable associations have been observed in
serogroup A, X and W-135 meningococci in Africa over a
45-year period (Beernink et al., 2009b). It should be noted,
however, that while these associations exist, they are not
absolute. For example, while most of the ST-32 complex
isolates were peptide allele 1, there was an isolate with the
peptide allele 13, and several of the complexes, while they
may have a dominant allele type, can also contain other
alleles. The ST-41/44 complex in particular was hetero-
geneous, with multiple allele types (Bambini et al., 2009;
Beernink et al., 2007; Jacobsson et al., 2006; Masignani et
al., 2003). The reasons for these associations are not fully
understood, but models of strain structure in recombining
pathogens show that immune selection can, counter-
intuitively, lead to the stable associations of antigenic
variants characteristic of meningococcal hyperinvasive
lineages (Gupta et al., 1996; Callaghan et al., 2008;
Buckee et al., 2008).
The availability of protein structures for fHbp, including
one with the protein bound to fH (Schneider et al., 2009),
allowed analysis of the sequence variability of regions
encoding different structural and functional domains.
Variation in peptide sequence is present throughout
fHbp, rather than being limited to particular variable
regions as is the case in the PorA and PorB2 (but not
PorB3) porins and FetA. Most fHbp diversity was found in
the C-terminal region (~158 aa in length) of fHbp, while
there was less in the N-terminal region (~ 105 aa in
length), which contained a domain that anchors the
protein to the cell membrane (Mascioni et al., 2009).
Other invariant regions of the protein are those involved
with fH interaction [particularly within subfamilies/var-
iants, although some of the interaction residues show some
polymorphism (Schneider et al., 2009)], and residues that
make up hydrophobic cores of the b-barrels and the points
of contact between the N- and C-terminal domains
(Mascioni et al., 2009).
The selection pressures acting on fHbp were deduced by
means of a Bayesian algorithm, which has a number of
advantages over the maximum-likelihood approaches used
previously to analyse selection pressures on the PorB
protein (Urwin et al., 2002), and the results compared with
those obtained in functional studies. Epitope mapping has
identified the residue Arg
204 as being essential for the
binding of a bactericidal mAb (Giuliani et al., 2005;
Scarselli et al., 2009). Residues also identified as potentially
involved in a conformational epitope with Arg
204 are
Glu
146–Arg
149 (Cantini et al., 2006; Scarselli et al., 2009;
Welsch et al., 2004). Due to their placement and clustering
in structural models, it is thought that these residues could
make up a bactericidal epitope in the C-terminal region
with the potential cooperation of other residues (Cantini et
al., 2006; Scarselli et al., 2009), and they have been shown
to be placed away from the fH recognition site and
therefore may not interfere with fH binding (Schneider
et al., 2009). The selection analyses identified these residues
as displaying evidence of immune selection on the
subfamily B/variant 1 protein, underlining their potential
relevance as protective epitopes. One of these residues, 151
(147 in subfamily B/variant 1), also showed evidence of
positive selection in subfamily A/variant 2.
Other protective epitopes identified to date include
residues 121–122 present in subfamily B/variant 1 proteins,
residues between 25 and 59 present in subfamily A/variant
2 and subfamily B/variant 1, and residues between
positions 174 and 216 of variant 2 and 3 proteins
(Beernink & Granoff, 2008; Beernink et al., 2009a, 2008).
Particularly in meningococci expressing fHbp at low levels,
these epitopes can induce bactericidal activity by eliciting
cooperative pairs of mAbs that also inhibit fH binding,
thus increasing complement-mediated activity (Beernink
et al., 2008). The selection analysis provided evidence for
positive selection in a region that partially overlapped with
one of these putative bactericidal epitopes found in the C-
terminal region of the subfamily A/variant 2 and subfamily
A/variant 3 proteins, i.e. residue 174. These results are very
encouraging in that such analyses can be used to predict
Meningococcal factor H-binding protein diversity
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bacterial proteins.
Molecular epidemiology has played a major role in the
development, implementation and study of meningococcal
vaccines (Bjune et al., 1991; Maiden et al., 2008;
O’Hallahan et al., 2005; Rodriguez et al., 1999). For
candidate protein components it is essential to determine
the number of variants required and to identify those likely
to provide the broadest possible protection, ideally before a
vaccine formulation is tested in humans. Although the use
of functional assays is important, nucleotide and peptide
sequence diversity give important guides to this process. In
the case of fHbp, the existence of multiple variants and the
evidence for particular epitopes under immune selection
indicate that, as for other meningococcal antigens, it will be
important to use vaccine formulations with multiple
components to achieve broad coverage, particularly as it
has been shown that cross-protection between the two
major subfamilies and within subfamily A, variants 2 and 3,
is limited (Beernink et al., 2007; Fletcher et al., 2004;
Masignani et al., 2003). An alternative strategy is to create
C. Brehony, D. J. Wilson and M. C. J. Maiden
4166 Microbiology 155chimeric proteins containing domains from the different
subfamilies/variants (Beernink & Granoff, 2008). However
multivalency is achieved, the optimum number of variants
to be used will depend on a combination of molecular
epidemiological and functional studies. Furthermore, the
lifespan of such vaccines will depend on the dynamics of
fHbp evolution in natural populations of meningococci
and any possible effects of vaccination on this process. The
nomenclature scheme and analytical framework described
here should contribute to assembling the information
required to answer these questions.
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